Upregulation of TBX21 or GATA3 and their target genes (EOMES, CXCR3, IL2RB, CCL3, IFNγ, and CCR4, IL18RA, CXCR7, IK, respectively) was previously shown to distinguish two subclasses of PTCL-NOS with distinct clinical outcomes [6,27]. This evidence concerns the gene IL18R1 and mature T-cell and NK-cell non-Hodgkin lymphoma.